eP123 Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study

Richtig, E. and Loquai, C. and Forschner, A. and Gutzmer, R. and Hassel, J. C. and Utikal, J. S. and Haferkamp, Sebastian and Meier, F. and Debus, D. and Dummer, R. and Von Moos, R. A. F. and Thompson, J. and Gengenbacher, L. and Michie-Lin, O. and Hoeller, C. and Schadendorf, D. (2022) eP123 Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: updated data from the long-term, multicenter, multinational, prospective, noninterventional BERING(MELANOMA) study. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Full text not available from this repository.

Item Type:	Conference or Workshop Item (Poster)
Subjects:	600 Technology > 610 Medical sciences Medicine
Divisions:	Medicine > Lehrstuhl für Dermatologie und Venerologie
Depositing User:	Petra Gürster
Date Deposited:	12 Oct 2023 07:41
Last Modified:	12 Oct 2023 07:41
URI:	https://pred.uni-regensburg.de/id/eprint/58774

Actions (login required)

View Item